La traduction est en cours. L’article original est affiché.
Amgen AMGN reported third-quarter 2026 adjusted earnings of $6.45 per share, up 14% year over year, driven primarily by higher revenues, which offset the impact of higher costs. Earnings per share beat the Zacks Consensus Estimate of $5.74. Total revenues increased 8% year over year to $10.37 billion, surpassing the consensus estimate of $9.95 billion. Product sales grew 8% to $9.88 billion, driven by higher volumes. Seventeen products delivered double-digit sales growth during the quarter. AMGN's Bone and Heart Drugs Deliver Strong Growth Repatha sales surged 37% year over year to $1.09 billion, exceeding the Zacks Consensus Estimate of $1.04 billion. The increase was driven by volume growth.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.